The genetic background of antidepressant response represents a unique opportunity to identify biological markers of treatment outcome. Encouraging results alternating with inconsistent findings made antidepressant pharmacogenetics a stimulating but often discouraging field that requires careful discussion about cumulative evidence and methodological issues.
Fabbri, C., Minarini, A., Niitsu, T., Serretti, A. (2014). Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 10(8), 1093-1118 [10.1517/17425255.2014.928693].
Understanding the pharmacogenetics of selective serotonin reuptake inhibitors
FABBRI, CHIARA;NIITSU, TOMIHISA;SERRETTI, ALESSANDRO
2014
Abstract
The genetic background of antidepressant response represents a unique opportunity to identify biological markers of treatment outcome. Encouraging results alternating with inconsistent findings made antidepressant pharmacogenetics a stimulating but often discouraging field that requires careful discussion about cumulative evidence and methodological issues.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
